Immunocore Q2 2025: KIMMTRAK revenue $98M (+30% YoY); net loss $10.3M

Immunocore Holdings plc

2025-Q2 EPS reported -$0.11 revenue$191,845,000

Q2 2025 net product sales of $98.0M, up 30% vs. $75.3M in Q2 2024; US sales $64.1M, Europe $33.0M.
Net loss of $10.3M ($0.20 per share) compared to net loss of $11.6M ($0.23 per share) in Q2 2024.
Cash, equivalents & marketable securities of $882.8M as of June 30, 2025; expects ~$65M in rebate payouts.
Phase 3 TEBE-AM trial (cutaneous melanoma) on track to complete enrollment in 1H 2026.
PRISM-MEL-301 (brenetafusp) dose selection expected in 2H 2025; IDMC recommended continue with no changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.